Aethlon Medical, Inc. (NASDAQ:AEMD) Short Interest Down 46.7% in March

Aethlon Medical, Inc. (NASDAQ:AEMD) was the target of a significant decrease in short interest during the month of March. As of March 15th, there was short interest totalling 255,400 shares, a decrease of 46.7% from the February 28th total of 479,400 shares. Based on an average daily trading volume, of 3,140,000 shares, the short-interest ratio is presently 0.1 days. Currently, 1.8% of the shares of the stock are short sold.

Analyst Ratings Changes

A number of equities analysts recently weighed in on the stock. StockNews.com initiated coverage on shares of Aethlon Medical in a research report on Friday. They set a “sell” rating on the stock. HC Wainwright restated a “buy” rating and set a $7.00 target price on shares of Aethlon Medical in a report on Monday, March 10th.

Hedge Funds Weigh In On Aethlon Medical

Several institutional investors and hedge funds have recently bought and sold shares of the company. Renaissance Technologies LLC purchased a new stake in shares of Aethlon Medical during the 4th quarter valued at approximately $25,000. Allegiance Financial Group Advisory Services LLC purchased a new position in Aethlon Medical in the fourth quarter worth approximately $26,000. Sassicaia Capital Advisers LLC acquired a new stake in Aethlon Medical during the fourth quarter worth $31,000. Virtu Financial LLC purchased a new stake in Aethlon Medical in the fourth quarter valued at $81,000. Finally, Boothbay Fund Management LLC purchased a new stake in Aethlon Medical in the fourth quarter valued at $186,000. 1.99% of the stock is currently owned by institutional investors and hedge funds.

Aethlon Medical Stock Down 8.6 %

Shares of NASDAQ:AEMD opened at $0.37 on Friday. Aethlon Medical has a 52-week low of $0.24 and a 52-week high of $1.79. The stock has a market cap of $5.30 million, a P/E ratio of -0.23 and a beta of 1.80. The business has a fifty day moving average of $0.56 and a two-hundred day moving average of $0.50.

Aethlon Medical (NASDAQ:AEMD) last announced its quarterly earnings data on Wednesday, February 12th. The medical equipment provider reported ($0.13) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.09. On average, equities analysts anticipate that Aethlon Medical will post -0.73 earnings per share for the current year.

About Aethlon Medical

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation.